rethinkPeptides Search
Menu
Study breakdown

Brain Inflammation Triggers Protective Neuropeptides PACAP and VIP as a Defense Response

evidence
The takeaway

Chronic brain inflammation driven by IL-6 triggers increased expression of the neuroprotective peptides PACAP and VIP, likely as the brain's built-in defense mechanism against neuroinflammatory damage.

5 targets upregulated

PACAP, VIP, and all three of their receptors (PAC1, VPAC1, VPAC2) were significantly increased in inflamed brains

What the researchers found

GFAP-IL6 transgenic mice (with astrocyte-targeted IL-6 production) showed significantly increased transcripts and protein levels of both PACAP and VIP, plus their receptors PAC1, VPAC1, and VPAC2, in both cerebrum and cerebellum compared to wild-type littermates. This was accompanied by robust activation of JAK/STAT3, NF-κB, and ERK1/2MAPK signaling pathways. Blocking IL-6 trans-signaling (using sgp130Fc co-expression) reduced VIP expression and attenuated STAT3 and NF-κB activation, but failed to rescue PACAP levels, receptor expression, or ERK1/2MAPK phosphorylation — indicating PACAP induction involves trans-signaling-independent mechanisms.

Why it matters

Neuroinflammation is a common feature of Alzheimer's, Parkinson's, multiple sclerosis, and other brain diseases. Understanding that the brain has a built-in neuropeptide defense system that activates in response to inflammation could lead to new therapeutic strategies — potentially boosting PACAP and VIP levels to enhance the brain's natural protective response.

How the study worked

Researchers used GFAP-IL6 transgenic mice with CNS-restricted, astrocyte-targeted IL-6 production, compared to wild-type littermates. Bi-genic GFAP-IL6/sgp130Fc mice were used to test whether blocking IL-6 trans-signaling would rescue neuropeptide changes. PACAP and VIP transcript and protein levels were measured in cerebrum and cerebellum, along with receptor expression and activation of JAK/STAT3, NF-κB, and ERK1/2MAPK signaling pathways using RT-qPCR, protein assays, and immunostaining.

What this study cannot tell us

This was a transgenic mouse study with artificial IL-6 overexpression, which may not fully replicate the nuanced inflammatory processes in human neurodegenerative diseases. The forced IL-6 expression is constitutive and extreme, unlike the fluctuating inflammation seen in clinical conditions. The study did not assess whether the PACAP/VIP upregulation actually conferred neuroprotection in these mice. Behavioral and cognitive outcomes were not measured.

How to read the evidence

This is a well-designed transgenic mouse study with mechanistic depth, using bi-genic models to dissect signaling pathways. However, it is basic science research without clinical or behavioral validation.

When this study was published

Published in 2024, this study represents current research on the interplay between neuroinflammation and neuropeptide defense systems in the brain.

The bigger picture

PACAP and VIP are increasingly recognized as endogenous neuroprotective agents. This study reveals they are part of a homeostatic brain defense system that activates in response to inflammation. If this response can be therapeutically enhanced, it could provide a new approach to treating neurodegenerative diseases where inflammation drives brain damage.

Questions still open

  • Does the PACAP/VIP upregulation actually protect neurons in these inflamed brains, or is it insufficient to prevent damage?
  • Could exogenous PACAP or VIP administration enhance the brain's natural defense against neuroinflammation in conditions like Alzheimer's?
  • Why do PACAP and VIP respond differently to trans-signaling blockade, and what does this mean for therapeutic targeting?

Common questions

What are PACAP and VIP and why are they important?
PACAP and VIP are neuropeptides — small protein messengers in the brain — with well-established protective and anti-inflammatory properties. This study found that when the brain is chronically inflamed, it ramps up production of both peptides and their receptors, suggesting they are part of a natural defense system against neuroinflammatory damage.
Could this finding help treat brain diseases like Alzheimer's?
Potentially. Neuroinflammation is a key driver of Alzheimer's, Parkinson's, and other neurodegenerative diseases. If the brain's natural PACAP/VIP defense response is insufficient to prevent damage, boosting these neuropeptides therapeutically could provide a new treatment approach. However, this remains at the basic research stage.

Read the original research

Increased Expression of the Neuropeptides PACAP/VIP in the Brain of Mice with CNS Targeted Production of IL-6 Is Mediated in Part by Trans-Signalling.

International journal of molecular sciences, 25(17)

Citation

Castorina, Alessandro; Scheller, Jurgen; Keay, Kevin A; Marzagalli, Rubina; Rose-John, Stefan; Campbell, Iain L. (2024). Increased Expression of the Neuropeptides PACAP/VIP in the Brain of Mice with CNS Targeted Production of IL-6 Is Mediated in Part by Trans-Signalling.. International journal of molecular sciences, 25(17). https://doi.org/10.3390/ijms25179453